IDEAYA Biosciences Q4 Results Misses Estimates

RTTNews | 333 days ago
IDEAYA Biosciences Q4 Results Misses Estimates

(RTTNews) - IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced net loss of $32.64 million or $0.52 per share, wider than $23.07 million or $0.50 per share in the prior-year quarter.

Collaboration revenues for the quarter declined to $3.92 million from $4.02 million in the same quarter last year.

On average, ten analysts polled by Thomson Reuters expected the company to report a loss of $0.47 per share on revenues of $8.84 million for the quarter. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
RTTNews | 516 days ago
Rate Cut Hopes Boost European Stock Markets

Rate Cut Hopes Boost European Stock Markets

Optimism over interest rate cuts had traders in a happy mood on Friday as the major European stock markets finished solidly to the upside, extending recent gains.
RTTNews | 1 day ago